Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma

Peters, Anju T.; Sagara, Hironori; Corren, Jonathan; Domingo, Christian; Altincatal, Arman; Soler, Xavier; Pandit-Abid, Nami; Crikelair, Nora; Rowe, Paul J.; Jacob-Nara, Juby A.; Deniz, Yamo

doi:10.1016/j.anai.2023.11.021

Annals of Allergy, Asthma & Immunology

2024

DOI: 10.1016/j.anai.2023.11.021

|View full text |Cite

Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma

Anju T. Peters,

Hironori Sagara,

Jonathan Corren

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

'Tis the season for dupilumab?

McCulloch,

Anderson

2024

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

'Tis the season for dupilumab?

McCulloch,

Anderson

2024

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

Biologics in Asthma

Desai,

Adrish,

Mohan

et al. 2024

Immunology and Allergy Clinics of North America

View full text Add to dashboard Cite

Therapeutic relevance of eosinophilic inflammation and airway viral interactions in severe asthma

Rupani,

Busse,

Howarth

et al. 2024

Allergy

View full text Add to dashboard Cite

The role of eosinophils in airway inflammation and asthma pathogenesis is well established, with raised eosinophil counts in blood and sputum associated with increased disease severity and risk of asthma exacerbation. Conversely, there is also preliminary evidence suggesting antiviral properties of eosinophils in the airways. These dual roles for eosinophils are particularly pertinent as respiratory virus infections contribute to asthma exacerbations. Biologic therapies targeting key molecules implicated in eosinophil‐associated pathologies have been approved in patients with severe asthma and, therefore, the effects of depleting eosinophils in a clinical setting are of considerable interest. This review discusses the pathological and antiviral roles of eosinophils in asthma and exacerbations. We also highlight the significant reduction in asthma exacerbations seen with biologic therapies, even at the height of the respiratory virus season. Furthermore, we discuss the implications of these findings in relation to the role of eosinophils in inflammation and antiviral responses to respiratory virus infection in asthma.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma

Cited by 3 publications

References 27 publications

'Tis the season for dupilumab?

'Tis the season for dupilumab?

Biologics in Asthma

Therapeutic relevance of eosinophilic inflammation and airway viral interactions in severe asthma

Contact Info

Product

Resources

About